The agreement is between Medpro Pharmaceuticals, a subsidiary of Cipla Medpro and Teva Pharmaceuticals, an affiliate of Teva Pharmaceuticals Industries, the company said in a filing to the Bombay Stock Exchange (BSE).

The collaboration with Teva in South Africa aims to provide South Africans with access to a broad range of affordable medicines. The deal will include oncology, central nervous system, women’s health, cardiovascular, ophthalmology, and other speciality products.

South Africa’s generics utilization rate in 2012 was 53.4%, according to the 2012 Mediscor Medicines Review (MMR). Cipla gained a 25% stake in the manufacturing division of Cipla Medpro – South Africa’s third largest drugmaker – back in 2010 [1].

Related articles
South African HCPs told to ‘get their facts straight’ on generics

The status of generic substitution in South Africa

Reference
1.   GaBI Online - Generics and Biosimilars Initiative. India’s top pharma company strengthens ties with South Africa [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Nov 7]. Available from: www.gabionline.net/Generics/News/India-s-top-pharma-company-strengthens-ties-with-South-Africa 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro PharmaCommunications International. All Rights Reserved.